Cargando…

A Comparative Study of IVIG versus IVIG with IV Methylprednisolone in Guillain–Barre Syndrome

Detalles Bibliográficos
Autores principales:	Bhattiprolu, Rahi Kiran, Sardana, Vijay, Maheshwari, Dilip, Bhushan, Bharat, Shringi, Prashant, Jain, Pallav, Shah, Vaishal, Patel, Bhavin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001426/ https://www.ncbi.nlm.nih.gov/pubmed/32055134 http://dx.doi.org/10.4103/aian.AIAN_378_19

Ejemplares similares

IVIG Treatment and Prognosis in Guillain–Barré Syndrome
por: van Doorn, Pieter A., et al.
Publicado: (2010)

IVIg‐induced plasmablasts in patients with Guillain‐Barré syndrome
por: Brem, Maarten D., et al.
Publicado: (2018)

Methylprednisolone Pulse Therapy or Additional IVIG for Patients with IVIG-Resistant Kawasaki Disease
por: Wang, Zhouping, et al.
Publicado: (2020)

Transfusion-Related Acute Lung Injury due to Iatrogenic IVIG Overdose in Guillain–Barre Syndrome
por: Ray, Sanghamitra, et al.
Publicado: (2019)

Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome
por: Winters, Jeffrey L, et al.
Publicado: (2011)

A CASE OF IVIG REFRACTORY GUILLAIN-BARRÉ SYNDROME IN THE SETTING OF SUBCLINICAL COVID-19 INFECTION
por: DELEVEAUX, SPENCER, et al.
Publicado: (2021)

Role of Surgical Procedures (VP Shunt and ETV) in Tuberculous Meningitis with Hydrocephalus (TBMH): A Systematic Review
por: Bhushan, Bharat, et al.
Publicado: (2021)

Treatment of scleromyxedema with IVIg
por: Moser, David W, et al.
Publicado: (2012)

Circulating Th17, Th22, and Th1 Cells Are Elevated in the Guillain-Barré Syndrome and Downregulated by IVIg Treatments
por: Li, Shujuan, et al.
Publicado: (2014)

Dengue Fever with Facial Palsy: A Rare Neurological Manifestation
por: Sardana, Vijay, et al.
Publicado: (2019)

Cooling down VITT with IVIG
por: Lentz, Steven R.
Publicado: (2021)

Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease
por: Han, Chun-Ling, et al.
Publicado: (2018)

Study on the Treatment of ITP Mice with IVIG Sourced from Distinct Sex-Special Plasma (DSP-IVIG)
por: Zhang, Wei, et al.
Publicado: (2023)

Eczematous reaction to IVIG for the treatment of dermatomyositis()()
por: Berk-Krauss, J., et al.
Publicado: (2018)

Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study
por: Zhu, Xiao-Lu, et al.
Publicado: (2022)

Therapeutic Window of Intravenous Immunoglobulin (IVIG) and its correlation with IVIG-resistant in Kawasaki Disease: a retrospective study
por: Cai, Jiang Hui, et al.
Publicado: (2022)

Correlation between the Level of Inflammatory Cytokines and Prognosis in Children with IVIG-sensitive Kawasaki Disease and IVIG-resistant Kawasaki Disease
por: Zhang, Hao, et al.
Publicado: (2022)

IVIG Effects on Erythrocyte Sedimentation Rate in Children
por: Salehzadeh, Farhad, et al.
Publicado: (2014)

Tregitope Peptides: The Active Pharmaceutical Ingredient of IVIG?
por: De Groot, Anne S., et al.
Publicado: (2013)

IVIG regulates the survival of human but not mouse neutrophils
por: Schneider, Christoph, et al.
Publicado: (2017)

Intravenous Immunoglobulins: Evolution of Commercial IVIG Preparations
por: Hooper, John A.
Publicado: (2008)

Unraveling the mechanisms of IVIG immunotherapy in MIS-C
por: Ganigara, Madhusudan, et al.
Publicado: (2021)

Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics
por: DeBiasi, Roberta L.
Publicado: (2021)

MIS-C Treatment: Is IVIG Always Necessary?
por: Licciardi, Francesco, et al.
Publicado: (2021)

Plasma exchange (PE) versus intravenous immunoglobulin (IVIG) for the treatment of Guillain-Barré syndrome (GBS) in patients with severe symptoms: A systematic review and meta-analysis
por: Zaki, Hany A., et al.
Publicado: (2023)

Determination of pain and response to methylprednisolone in Guillain-Barré syndrome
por: Ruts, Liselotte, et al.
Publicado: (2007)

SCIg vs. IVIg: let’s give patients the choice!
por: Samaan, Kathryn K, et al.
Publicado: (2014)

Dose‐dependent inhibition of demyelination and microglia activation by IVIG
por: Winter, Meike, et al.
Publicado: (2016)

IgG Glyco-Engineering to Improve IVIg Potency
por: Bruggeman, Christine W., et al.
Publicado: (2018)

Corrigendum: MIS-C Treatment: Is IVIG Always Necessary?
por: Licciardi, Francesco, et al.
Publicado: (2022)

CIDP prognosis in patients with IVIG treatment‐related fluctuations
por: Cook, Melissa, et al.
Publicado: (2022)

Hydroxychloroquine-Induced Myopathy Responding to Intravenous Immunoglobulin (IVIG)
por: Almoallim, Hani, et al.
Publicado: (2023)

Intravenous Immunoglobulin G (IVIG) Need Assessment Survey Toward Local Manufacturing of IVIG Using a Mini-Pool Plasma Fractionation Technique
por: Bekele, Bisrat, et al.
Publicado: (2023)

Active regulatory T-cells contribute to broadened T-cell repertoire diversity in ivIg-treated SLE patients
por: Costa, Nuno, et al.
Publicado: (2011)

Tubulointerstitial nephritis complicating IVIG therapy for X-linked agammaglobulinemia
por: Sugimoto, Keisuke, et al.
Publicado: (2014)

Is response to IVIG in Chronic Idiopathic Urticaria related to presense of autoantibodies?
por: Rosenfield, Lana, et al.
Publicado: (2014)

Molecular factors modulating the anti-inflammatory activity of IVIg in ITP
por: Schwab, Inessa, et al.
Publicado: (2012)

Persistent Immune Activation in CVID and the Role of IVIg in Its Suppression
por: Paquin-Proulx, Dominic, et al.
Publicado: (2014)

Developing the IVIG biomimetic, Hexa-Fc, for drug and vaccine applications
por: Czajkowsky, Daniel M., et al.
Publicado: (2015)

Tregitopes and impaired antigen presentation: Drivers of the immunomodulatory effects of IVIg?
por: Sordé, Laetitia, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cgsraa7tcuu2lv8sgj8glphbp8